12-24 Hours
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Hemorise 500
The ACME Laboratories Ltd.
Generic: Ferric Carboxymaltose
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Hemorise 500. Please consult your doctor.
CONSULT YOUR DOCTOR
Hemorise 500 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
SAFE IF PRESCRIBED
Hemorise 500 is safe to use during breastfeeding. Human studies suggest that the drug does not pass into the breastmilk in a significant amount and is not harmful to the baby.
SAFE
Hemorise 500 does not usually affect your ability to drive.
SAFE IF PRESCRIBED
Hemorise 500 is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Hemorise 500 may not be needed in these patients. Please consult your doctor.
CAUTION
Hemorise 500 should be used with caution in patients with liver disease. Dose adjustment of Hemorise 500 may be needed. Please consult your doctor.
Medicine Overview of Hemorise 500mg/10ml Injection
Introduction
Hemorise 500 is an iron replacement medicine. It is used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body (iron-deficiency anemia). Iron is needed to produce the red blood cells that carry oxygen around your body. Hemorise 500 is given by injection or infusion (saline drip) into a vein by your doctor or nurse. You will be watched carefully to make sure you do not have an allergic reaction. It is usually given as two doses, seven days apart. Your doctor will decide how much and how...
... Show moreUses of Hemorise 500
- Iron deficiency anemia
Side effects of Hemorise 500
Common
- Injection site reactions (pain, swelling, redness)
- Nausea
- Vomiting
- Dark colored stool
- Headache
How to use Hemorise 500
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Hemorise 500 works
Hemorise 500 is an anti-anemic medication. It replenishes the iron stores in your body. Iron is vital for the formation of new red blood cells and hemoglobin, a substance that gives these cells the ability to transport oxygen.
What if you forget to take Hemorise 500?
If you miss a dose of Hemorise 500, please consult your doctor.
Quick Tips
- Hemorise 500 is used for the treatment of iron deficiency, when oral iron preparations are ineffective or cannot be used.
- Your doctor or nurse will administer it by injection. You will be observed for at least 30 minutes after each injection as it may cause allergic reaction.
- Your blood pressure and blood iron levels will be regularly monitored during treatment with this medication.
- Inform your doctor if you are taking any iron-containing products by mouth.
- Do not consume alcohol when on treatment with this medicine as it may worsen its side effects.
- It may cause your stools to become black or dark in color. This is normal and harmless.
Brief Description
Indication
Iron deficiency anemia
Administration
IV Preparation
For IV infusion, dilute in up to 250 mL 0.9% NaCl; resulting concentration should be >2 mg/mL
IV Administration
IV push: May administer undiluted at rate of 100 mg/minute
IV infusion: Dilute dose in up to 250 mL 0.9% NaCl and infuse over at least 15 minutes
Adult Dose
Injection
Iron-deficiency Anemia
Indicated for treatment of iron deficiency anemia (IDA) in adults who have intolerance or an unsatisfactory response to oral iron; also indicated for IDA in adults with nondialysis dependent chronic kidney disease
>50 kg: 750 mg IV once, follow 7 days later with second 750 mg dose; not to exceed cumulative dose of 1500 mg per course
<50 kg: 15 mg/kg IV once, follow 7 days later with second dose; not to exceed 1500 cumulative dose per course
Child Dose
Safety and efficacy not established
Contraindication
Hypersensitivity to any of its components.
Mode of Action
Non-dextran, IV is a colloidal iron hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron; replaces iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin
Macrophage engulf FCM from blood and control iron release. Transferrin saturates and , Iron into the liver, spleen and Bone marrow.
Precaution
Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Ferric carboxymaltose. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Ferric carboxymaltose administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Ferric carboxymaltose when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but not limited to, pruritus,...
... Show moreSide Effect
1-10%
Nausea (7.2%),Hypertension (3.8%),Flushing (3.6%),Decreased blood phosphorus (2.1%),Dizziness (2%),Vomiting (1.7%),Pruritus (1.5%),Rash (1.5%),Urticaria (1.5%),Wheezing (1.5%),Injection site discoloration (1.4%),Headache (1.2%),Increased alanine aminotransferase (1.1%),Dysgeusia (1.1%),Hypotension 1%)
<1%
Constipation (0.5%),Serious anaphylactic/anaphylactoid reactions (0.1%)
Pregnancy Category Note
Pregnancy Studies on use in pregnant women have not reported adverse developmental outcomes; however, these studies cannot establish or exclude absence of any drug-related risk during pregnancy because studies were not designed to assess for risk of major birth defects; there are risks to mother and fetus associated with untreated iron deficiency anemia (IDA) in pregnancy Untreated iron deficiency anemia (IDA) in pregnancy is associated with adverse maternal outcomes such as post-partum anemia; adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight Lactation Available published data on use of ferric carboxymaltose in lactating...
... Show moreব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
